The Food and Drug Administration on July 29 licensed the first freeze-dried plasma product ever approved for use in the United States, a landmark advance for battlefield and emergency trauma medicine that military and civilian medical leaders have sought for more than a decade.
Freeze-dried plasma can be stored at room temperature for extended periods and reconstituted with sterile water in minutes, making it dramatically more practical than traditional liquid plasma, which requires refrigeration and has a limited shelf life. The approval removes a longstanding barrier to delivering blood products in austere and remote settings.
The product has immediate applications for U.S. service members in combat zones, where the ability to rapidly administer plasma can mean the difference between life and death for troops with severe bleeding injuries. Military trauma surgeons have identified the lack of a shelf-stable plasma product as one of the most critical gaps in battlefield medicine.
Beyond the military, the approval stands to improve trauma care at civilian emergency departments, rural hospitals, and mass casualty events where maintaining cold-chain storage for blood products is difficult or impossible. Emergency medical services operating in remote areas will be able to carry the product on ambulances and helicopters.
French military forces have used freeze-dried plasma for decades, and U.S. military medical researchers have studied the French product extensively as a model. The FDA approval follows years of clinical trials and regulatory review specific to the U.S. market.
The FDA said the licensed product meets all safety and efficacy standards required for biological products. The agency did not immediately disclose the manufacturer or the projected timeline for commercial availability.